MONTE enables unified pan-cancer tumor purity estimation andmethylation correction from bulk DNA methylation arrays

Bulk DNA methylation profiling is widely used to study cancer epigenomics in clinical settings, but these measurements aggregate signals from malignant and non-malignant cells, introducing composition-dependent confounding that complicates tumor-intrinsic interpretation and cross-cohort analyses. While existing methods can estimate tumor purity and, in some cases, correct methylation measurements, they typically require cancer-specific reference models, matched normal samples, or predefined probe sets, limiting their applicability to rare cancers, different clinical cohorts, and cross-dataset comparisons. We present MONTE (Methylation-based Observation Normalization and Tumor purity Estimation), a unified, cancer label-free framework for tumor purity inference and CpG-resolved methylation correction from bulk DNA methylation data. MONTE learns probe-wise relationships between methylation and tumor purity using an empirical Bayes-moderated linear model and infers purity in new samples via signal-to-noise weighted aggregation, without requiring matched normals, cancer labels, or predefined probe sets. A single pan-cancer MONTE model outperforms existing cancer-specific methods for purity estimation across 21 cancer types, generalizes across purity references, and runs orders of magnitude faster on full-dataset analyses. MONTE also introduces Bayesian transfer learning, which enables efficient recalibration to alternative purity definitions, validated on three independent external cohorts. Methylation correction with MONTE further amplifies tumor-relevant regulatory signal and improves the reproducibility of differential methylation analyses. By unifying purity estimation and correction in a single flexible, scalable, and interpretable framework, MONTE broadens the accessibility of tumor-intrinsic methylation analysis across cancer types and datasets.